ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Cancer"

  • Abstract Number: 364 • 2018 ACR/ARHP Annual Meeting

    Elevated sCD40L As a Predictive Biomarker of Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors

    Nicholas Meti1, Khashayar Esfahani1,2, Ines Colmegna1,3, Marvin J. Fritzler4, Nathalie A. Johnson1,5, Ciriaco Piccirillo1,6, Wilson H. Miller Jr.1,2 and Marie Hudson1,7, 1Department of Medicine, McGill University, Montreal, QC, Canada, 2Department of Oncology, McGill University, Jewish General Hospital, Rossy Cancer Network, Montreal, QC, Canada, 3Division of Rheumatology, McGill University Health Centre, Montreal, QC, Canada, 4Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 5Division of Hematology, Jewish General Hospital, Montreal, QC, Canada, 6Department of Microbiology & Immunology, McGill University, Montreal, QC, Canada, 7Division of Rheumatology, Jewish General Hospital, Montreal, QC, Canada

    Background/Purpose: The clinical use of immune checkpoint inhibitors (ICI) has led to outstanding clinical outcomes in previously refractory cancers, but ICI have also been associated…
  • Abstract Number: 710 • 2018 ACR/ARHP Annual Meeting

    An Analysis of Cell-of-Origin in Diffuse Large B-Cell Lymphoma in Systemic Lupus Erythematosus, Including Molecular and Clinical Factors Associated with Survival

    Basile Tessier-Cloutier1, David Twa2, Eva Baecklund3, Randy Gascoyne4, Nathalie A. Johnson5, Carin Backlin3, Diane L. Kamen6, Ann E. Clarke7, Rosalind Ramsey-Goldman8, Jennifer LF Lee9, Pedro Farinha4 and Sasha Bernatsky10, 1Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada, 2Department of Medicine, University of British Columbia, Vancouver, BC, Canada, 3Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 4Department of Pathology, British Columbia Cancer Agency, Vancouver, BC, Canada, 5Department of Oncology, McGill University, Montreal, QC, Canada, 6Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, 7Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 8FSM, Northwestern University, Chicago, IL, 9Medicine, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 10Divisions of Rheumatology and Clinical Epidemiology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose: Systemic lupus erythematosus (SLE) is associated with increased risk of diffuse large B-cell lymphoma (DLBCL). DLBCL is routinely classified by cell-of-origin (COO), with non-germinal…
  • Abstract Number: 814 • 2018 ACR/ARHP Annual Meeting

    NON Diffuse SSc, Peripheral Neuropathy, Concomitant Sjogren Syndrome and ANTI-RNA Polymerase III Represent Risk Factors for the Higher Frequency of Cancer in a Large Single Cohort of Patients with Systemic Sclerosis

    Ana Paula Luppino-Assad1, Adriana Bortoluzzo2, Henrique Carriço da Silva3, Danieli Andrade4 and Percival Sampaio-Barros4, 1Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., sao paulo, Brazil, 2c Instituto Insper de Educação e Pesquisa, São Paulo, SP, Brasil, sao paulo, Brazil, 3Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., SAO PAULO, Brazil, 4Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., São Paulo, Brazil

    Background/Purpose: A higher prevalence of cancer has been described in patients with systemic sclerosis (SSc), but the magnitude of this risk and the type of…
  • Abstract Number: 880 • 2018 ACR/ARHP Annual Meeting

    Serum Cytokine and Chemokine Concentrations Predict Incident Cancer in US Veterans with Rheumatoid Arthritis

    Bryant R. England1, Harlan Sayles2, Punyasha Roul2, Apar Ganti3, Jeremy Sokolove4, William H. Robinson5, Grant W. Cannon6, Brian Sauer7, Joshua Baker8, Geoffrey M. Thiele2 and Ted R. Mikuls9, 1Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, 2University of Nebraska Medical Center, Omaha, NE, 3VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE, 4Division of Immunology and Rheumatology, Stanford University Medical Center, Mountain View, CA, 5Stanford University, Palo Alto, CA, 6Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 7Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 8Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, PA, 9VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: The immune system plays a critical protective role in cancer (CA) development. Perturbations in immune signaling, including cytokine dysregulation, may disrupt this homeostatic balance.…
  • Abstract Number: 1522 • 2018 ACR/ARHP Annual Meeting

    Time Dependent Effect of Biologic Therapy on Overall Survival in Patients with Rheumatoid Arthritis and Cancer

    Xerxes Pundole1, Natalia Zamora2, Harish Siddhanamatha3, Jean Tayar4, Cheuk Hong Leung5, Heather Lin6 and Maria Suarez-Almazor7, 1Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, 2Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, 3The University of Texas Health Science Center, School of Biomedical Informatics, Houston, TX, USA, Houston, TX, 4Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX, 5Department of Biostatistics, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, 6Biostatistics, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, 7Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

    Background/Purpose: Biologic disease-modifying anti-rheumatic drugs (bDMARDs) are commonly used in the treatment of rheumatoid arthritis (RA). But the use of bDMARDs in patients with RA…
  • Abstract Number: 2143 • 2018 ACR/ARHP Annual Meeting

    Lymphoproliferative Malignancy in Psoriatic Arthritis and the Role of Systemic Immunosuppressive Therapies

    Linh Truong1 and Maida Wong2, 1Internal Medicine, University of California, Irvine, Orange, CA, 2Division of Rheumatology, University of California, Irvine, Orange, CA

    Background/Purpose: Psoriatic arthritis (PsA) is a systemic inflammatory disease that can have musculoskeletal (PsA-MsK) or concurrent MsK and skin (PsA-MsK/skin) manifestations, and the skin disease…
  • Abstract Number: 2160 • 2018 ACR/ARHP Annual Meeting

    Effect of the Metabolic Syndrome on Incident Vascular Events and Mortality in Four Rheumatic Diseases: An 8-Year Longitudinal Analysis

    Chi Chiu Mok1, Chiu Sum Chu1, Ling Yin Ho2, Kar Li Chan1, Sau Mei Tse1 and Chi Hung To3, 1Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, 2Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong, 3Medicine, Pok Oi Hospital, Hong Kong, Hong Kong

    Background/Purpose: To study the effect of the metabolic syndrome (MetS) on incident vascular events and mortality in 4 rheumatic diseases over an 8-years’ follow-up. Methods:…
  • Abstract Number: 2991 • 2018 ACR/ARHP Annual Meeting

    Malignancies In Giant Cell Arteritis- A Population-Based Cohort Study

    Pavlos Stamatis1, Carl Turesson2, Minna Willim3, Jan-Åke Nilsson4, Martin Englund5 and Aladdin Mohammad6, 1Clinical Sciences, Rheumatology Lund, Lund University, Lund, Sweden, 2Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 3Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden, 4Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, 5Clinical Sciences Lund, Clinical Epidemiology Unit, Lund University, Lund, Sweden, 6Department of Medicine, University of Cambridge, Cambridge, United Kingdom

    Background/Purpose: To investigate the cancer risk in patients with biopsy-proven giant cell arteritis (GCA). Methods: The study population consisted of 830 patients (74 % women)…
  • Abstract Number: 11L • 2017 ACR/ARHP Annual Meeting

    Risk of Second Malignant Neoplasm and Mortality in Rheumatoid Arthritis Patients Treated with Biological Dmards: A Danish Population-Based Cohort Study

    Lene Dreyer1, René Cordtz2, Inger Marie J. Hansen3, Lars Erik Kristensen4, Merete Lund Hetland5 and Lene Mellemkjær6, 1Center for Rheumatology and Spine Diseases, Gentofte University Hospital,Rigshospitalet, Hellerup, Denmark, 2Center for Rheumatology and Spine Diseases, Gentofte University Hospital, Rigshospitalet, Hellerup, Denmark, 3Department of Reumatology, OUH, Svendborg Hospital, Svendborg, Denmark, 4The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen F, Denmark, 5DANBIO, Glostrup Hospital.On behalf of all Depts of Rheumatology in Denmark.Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Glostrup, Denmark, 6Danish Cancer Society Research Center, Copenhagen, Denmark, Copenhagen, Egypt

    Background/Purpose: The safety of treatment with biological DMARDs (bDMARDs) has been carefully studied for the past 15 years, however, it is still largely unknown whether…
  • Abstract Number: 1227 • 2017 ACR/ARHP Annual Meeting

    Osteoporosis and Breast Cancer: Can FRAX-Based Risk Factors Accurately Predict Further Fractures at This Setting?

    Salvador López-Salguero1, Laura Ranieri2, Juan Carlos Ordoñez3, Mariano Andrés4,5, Jose Ponce6 and Isabel Ibero2, 1Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, 2Reumatología, Dpt. Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, 3RHEUMATOLOGY, Dpt. Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, 4Dpt. Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, 5Universidad Miguel Hernández, Elche, Spain, 6Oncología, Dpt. Oncology, Hospital General Universitario Alicante, Alicante, Spain

    Background/Purpose: Women with breast cáncer (BC) are at risk for the development of bone loss and osteoporosis (OP) mainly due to adjuvant therapies, as aromatase…
  • Abstract Number: 1228 • 2017 ACR/ARHP Annual Meeting

    Postmenopausal Breast Cancer Patients on Aromatase Inhibitor Therapy and Their Increased Risk of Fragility Fracture

    Anna Lafian1, Julia Suh2 and Karina Torralba3, 1Internal Medicine, Arrowhead Regional Medical Center, Colton, CA, 2Internal Medicine, Loma Linda University, Loma Linda, CA, 3Internal Medicine/Rheumatology, Loma Linda University, Loma Linda, CA

    Background/Purpose: Postmenopausal women with breast cancer have higher osteoporosis risk due to declining estrogen levels and use of aromatase inhibitors (AIs). The American Society of…
  • Abstract Number: 1606 • 2017 ACR/ARHP Annual Meeting

    Cancer in an SLE Inception Cohort: Smoking May out-Perform Tumor Markers As a Risk Predictor

    Sasha Bernatsky1, Murray Urowitz2, John G Hanly3, Ann E. Clarke4, Marvin J. Fritzler5, Caroline Gordon6, Juanita Romero-Diaz7, Graciela S. Alarcón8, Sang-Cheol Bae9, Michelle Petri10, Joan T. Merrill11, Daniel J. Wallace12, Paul R. Fortin13, Dafna D Gladman14, David A. Isenberg15, Anisur Rahman16, Susan Manzi17, Ola Nived18, Gunnar K. Sturfelt19, Christine A. Peschken20, Jorge Sanchez-Guerrero21, Guillermo Ruiz-Irastorza22, Cynthia Aranow23, Ronald F van Vollenhoven24, Asad Zoma25, Kristján Steinsson26, Munther A Khamashta27, Ellen M. Ginzler28, Anca Askanase29, Kenneth C. Kalunian30, Mary Anne Dooley31, S. Sam Lim32, Diane L. Kamen33, Søren Jacobsen34, Manuel Ramos-Casals35, Murat Inanc36, Jennifer LF Lee37 and Rosalind Ramsey-Goldman38, 1Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 2Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, 4Division of Rheumatology, University of Calgary, Calgary, AB, Canada, 5Medicine, University of Calgary, Calgary, AB, Canada, 6Rheumatology Research Group, Institute of Inflammation and Ageing,, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 7Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, 8University of Alabama at Birmingham, Birmingham, AL, 9Department of Rhematology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), 10Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, 11Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 12Rheumatology, Cedars-Sinai Medical Center, Beverly Hills, CA, 13Université Laval, CHU de Québec, Québec, QC, Canada, 14Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 15Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, 16Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, 17Medicine, Allegheny Health Network, Pittsburgh, PA, 18Department of Rheumatology, University Hospital, Lund, Sweden, 19Department of Rheumatology, Univ Hospital Lund, Lund, Sweden, 20RR 149G, Univ of Manitoba, Winnipeg, MB, Canada, 21Division of Rheumatology, Toronto Western Hospital, Toronto, AB, Canada, 22Biocruces Health Research Institute, Barakaldo, Spain, 23Autoimmune and Musculoskeletal Disease, The Feinstein Institute for Medical Research, Manhasset, NY, 24AMC, F4-214, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, 25University of Glasgow, Glaskow, United Kingdom, 26Rheumatology, Univ. Hospital, Reykjavik, Iceland, 27Lupus Research Unit, Lupus Research Unit, The Rayne Institute, King's College London School of Medicine, St Thomas' Hospital, London, United Kingdom, 28Rheumatology, Division of Rheumatology, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, 29Rheumatology, Columbia University, New York, NY, 30Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, 31UNC Kidney Centre, Chapel Hill, NC, 32Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, 33Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, 34Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, 35Hospital Clinic, Barcelona, Spain, 36Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 37Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 38FSM, Northwestern University, Chicago, IL

    Background/Purpose: We assessed incident cancers in a large inception SLE cohort, and examined demographic and clinical factors, including tumor-related autoantibodies against proliferating cell nuclear antigen…
  • Abstract Number: 2395 • 2017 ACR/ARHP Annual Meeting

    Recommendations on the Management of Rheumatoid Arthritis in Patients with Cancer: A Systematic Review of Clinical Practice Guidelines and Consensus Statements

    Maria A. Lopez-Olivo1, Ines Colmegna2, Aliza Matusevich1, Susan Ruyu Qi3, Natalia Zamora1, Robin Sharma1, Gregory Pratt4 and Maria Suarez-Almazor1, 1Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, 2Division of Rheumatology, Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada, Montreal, QC, Canada, 3Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada, Montreal, QC, Canada, 4Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX

    Background/Purpose: To compare the recommendations of clinical practice guidelines (CPGs) and consensus statements (CSs) regarding the management of rheumatoid arthritis (RA) in patients with cancer.…
  • Abstract Number: 2735 • 2017 ACR/ARHP Annual Meeting

    Is There an Association between Adult IgA Vasculitis and Cancer?

    Jaka Ostrovrsnik1, Ziga Rotar1, Rok Jese1, Matija Tomšič1,2 and Alojzija Hočevar1, 1Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 2University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia

    Background/Purpose: An increased incidence rate of cancer has been reported in adult patients with IgA vasculitis (IgAV). These conclusions are mostly based on observations in…
  • Abstract Number: 2739 • 2017 ACR/ARHP Annual Meeting

    Onco-Hematological Malignancies in Systemic Necrotizing Vasculitides: Pooled Analysis of Five Prospective, Randomized, Controlled Trials

    Lafarge Antoine1, Christian Pagnoux2, Xavier Puéchal3, Maxime Samson4, Mohamed Hamidou5, Alexandre Karras6, Thomas Quémeneur7, Matthieu Groh8, Luc Mouthon9, Loïc Guillevin for the French Vasculitis Study Group3 and Benjamin Terrier10, 1Medecine Interne, Hôpital Cochin, Paris, France, 2Mount Sinai Hospital, Toronto, ON, Canada, 3Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, 4Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, 5Medecine Interne, CHU Hôtel Dieu, Nantes, France, 6nephrology, HEGP, Paris, France, 7Service de néphrologie, médecine interne et vasculaire, Hôpital de Valenciennes, Valenciennes, France, 8National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, 9Université Paris Descartes Sorbonne Paris, Paris, France, 10Internal Medicine, Cochin University Hospital, Paris, France

    Background/Purpose: The use of long-term immunosuppressive agents in patients with systemic necrotizing vasculitides has dramatically improved the overall prognosis, but expose patients to potential severe…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology